[Real-life study of 7-year survival in patients treated with trastuzumab for HER2+ early breast cancer].
Fiche publication
Date publication
juin 2020
Journal
Bulletin du cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CURTIT Elsa
Tous les auteurs :
Saghatchian M, Curtit E, Coeffic D, Flinois A, Levy C
Lien Pubmed
Résumé
Despite improved prognosis of HER2 since the introduction of trastuzumab in the adjuvant setting of early breast cancer, disease recurrences still occur, particularly in certain patient subgroups. The objective of this real-life study conducted in France is to evaluate after 7 years, disease-free survival (DFS) and distant metastatic-free survival (MFS).
Mots clés
Breast cancer, Disease-free survival, Epidemiology, Sein, Survie sans maladie, Trastuzumab, Épidémiologie
Référence
Bull Cancer. 2020 Jun 9;: